Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of IPG1094 in Healthy Chinese Adults
NCT07679113Phase 1Recruiting
- Sponsor
- Nanjing Immunophage Biotech Co., Ltd.
- Start
- Jul 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of IPG1094 (2 arms), sponsored by Nanjing Immunophage Biotech Co., Ltd. Primary endpoints: Time to maximum concentration at Day 6, Plasma maximum concentration at Day 6 and 3 more. Started Jul 2026; status: recruiting.
02
Drugs
IPG1094
Beyond the preview
Go deeper on NCT07679113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07679113.